world
teeter
verg
massiv
influenza
face
pandem
exist
manufactur
unlik
suffici
product
capac
produc
new
vaccin
scale
speed
requir
protect
public
health
argu
countri
establish
vaccin
product
infrastructur
must
invest
greater
effort
resourc
develop
innov
dna
vaccin
technolog
ultim
may
empow
countri
produc
vaccin
loom
health
manufactur
crisi
world
health
organ
state
avian
flu
potenti
kill
mani
peopl
sever
acut
respiratori
syndrom
sar
date
account
death
june
confirm
death
total
infect
avian
influenza
subtyp
hemagglutinin
particular
concern
mutat
rapidli
document
capac
acquir
gene
virus
infect
anim
speci
case
transmiss
trace
contact
anim
viru
evolv
cross
speci
barrier
eas
health
offici
warn
catastroph
consequ
human
health
indirectli
global
economi
respons
unit
state
contract
million
dose
influenza
vaccin
itali
franc
anticip
stockpil
million
dose
recent
unit
kingdom
order
million
dose
antivir
drug
word
contract
anticip
order
must
stress
accord
abil
current
manufactur
produc
vaccin
drug
respons
pandem
woefulli
million
shot
per
lack
manufactur
capac
arisen
five
major
manufactur
londonbas
glaxosmithklin
parisheadquart
sanofiaventispasteur
merck
rahway
new
jersey
wyeth
madison
new
jersey
emeryvillebas
chiron
focu
produc
vaccin
flu
season
glaxosmithklin
sanofiaventispasteur
chiron
manufactur
distribut
flu
vaccin
chiron
run
manufactur
problem
time
plant
germani
sever
reason
compani
manufactur
vaccin
today
compar
compani
ref
one
contributor
sector
rel
poor
profit
margin
high
fix
cost
manufactur
today
entir
vaccin
market
estim
contrast
singl
blockbust
drug
may
make
compani
around
billion
annual
biggest
seller
new
yorkbas
pfizer
lipitor
atorvastatin
brought
billion
ref
overal
size
vaccin
market
estim
less
pharmaceut
govern
bulk
buy
price
control
help
increas
risk
liabil
exposur
vaccin
compar
therapeut
hand
increasingli
stringent
regulatori
condit
vaccin
test
licensur
product
markedli
increas
outlay
need
manufactur
facil
personnel
technolog
vaccin
long
process
time
difficult
thu
expens
produc
failur
product
batch
result
extrem
financi
ramif
manufactur
technolog
issu
stem
product
difficulti
crippl
vaccin
industri
lead
vaccin
shortag
financi
woe
compani
last
year
exampl
us
food
drug
administr
fda
caught
guard
shortag
flu
vaccin
caus
contamin
uk
plant
chiron
one
unit
state
two
major
supplier
aventi
pasteur
contract
flu
ad
wane
corpor
interest
sector
diminish
commerci
incent
innov
technolog
transfer
could
address
problem
current
influenza
vaccin
technolog
case
influenza
pandem
vaccin
one
key
intervent
crucial
stage
control
pandem
provid
mani
vaccin
dose
new
viral
strain
shortest
possibl
time
howev
shot
current
licens
use
base
ancient
technolog
biotechnolog
time
frame
current
chemic
inactiv
trival
influenza
vaccin
produc
coinfect
batch
egg
epidem
influenza
strain
anoth
strain
influenza
apuerto
grow
well
egg
hitandmiss
process
screen
infect
egg
recombin
vaccin
strain
multipli
effici
ova
also
provid
protect
epidem
strain
take
time
often
month
luck
face
influenza
pandem
approach
unlik
tenabl
fig
advent
revers
genet
enabl
precis
manipul
assembl
flu
viru
genom
vitro
creat
new
creat
vaccin
exampl
hemagglutinin
gene
alter
remov
motif
associ
virul
stitch
togeth
part
influenza
genom
make
replic
vaccin
strain
subsequ
use
live
prepar
chemic
estim
vaccin
strain
made
approach
four
week
wildtyp
viral
yet
efficaci
safeti
vaccin
begin
test
product
vaccin
batch
qualiti
control
product
finish
control
agenc
test
distribut
significantli
prolong
time
need
vaccin
administ
suscept
popul
fig
clearli
pandem
demand
influenza
vaccin
significantli
surpass
avail
suppli
exist
manufactur
pandem
strain
emerg
research
frantic
race
time
creat
effect
vaccin
although
stockpil
flu
vaccin
might
help
alway
possibl
new
epidem
strain
could
suffici
differ
human
vaccin
current
test
render
stockpil
ineffect
respons
put
forward
rang
idea
includ
exchang
clinic
trial
data
antigenspar
eg
use
adjuv
enhanc
antigen
effect
thu
stretch
limit
suppli
increas
fund
pandem
vaccin
taxoth
incent
industri
waiv
regulatori
licens
fee
solut
like
lot
technic
complex
allud
briefli
greatest
need
address
pandem
vaccin
product
lead
demand
forwardlook
innov
address
product
issu
rise
dna
vaccin
vaccin
base
plasmid
dna
offer
potenti
solut
loom
influenza
vaccin
crisi
platform
suffici
stage
develop
extens
experiment
work
clinic
consid
serious
vaccin
option
typic
dna
vaccin
protocol
individu
given
protein
antigen
dna
encod
antigen
dna
segment
encod
protein
antigen
incorpor
plasmid
dna
may
administ
way
convent
vaccin
plasmid
taken
relev
cell
type
usual
dendrit
cell
skin
muscl
capabl
replic
independ
chromosom
dna
transcrib
gene
encod
antigen
interest
fragment
express
protein
degrad
peptid
present
major
histocompat
complex
mhc
class
mhc
class
ii
molecul
depend
upon
cell
type
method
administr
gene
gun
inject
despit
product
small
amount
antibodi
cellular
respons
induc
compar
practic
edward
jenner
use
produc
first
smallpox
vaccin
unit
kingdom
document
china
earli
dna
vaccin
new
approach
inde
technic
feasibl
first
demonstr
year
ago
wolff
et
report
intramuscular
inocul
plasmid
dna
encod
report
gene
could
induc
express
without
need
special
deliveri
system
eg
viral
vector
work
laid
foundat
first
observ
ulmer
et
dna
vaccin
could
protect
anim
influenza
infect
first
report
use
plasmid
dna
vaccin
outsid
trial
condit
experiment
set
immun
california
condor
west
nile
almost
last
ditch
attempt
save
remain
endang
california
condor
us
center
diseas
control
prevent
cdc
atlanta
georgia
rush
plasmid
dna
vaccin
contain
piec
west
nile
viru
genom
encod
prm
pre
protein
entir
process
initi
develop
final
product
took
north
dakotabas
aldevron
compani
contract
cdc
manufactur
vaccin
approxim
one
month
creation
cell
bank
optim
manufactur
system
meant
larg
quantiti
plasmid
could
produc
significantli
faster
would
possibl
convent
vaccin
importantli
work
accord
cynthia
stringfield
veterinarian
lo
angel
zoo
condor
absolut
zero
neg
effect
blood
test
suggest
bird
fantast
immun
respons
promis
result
dna
vaccin
offer
sever
featur
dna
vaccin
make
appeal
convent
even
recombin
subunit
vaccin
firstli
dna
amen
manipul
express
recipi
cell
allow
greater
control
immun
process
platform
investig
determin
antigen
costimul
use
elicit
respons
eg
skin
muscl
cytokin
need
coexpress
whether
use
costimulatori
dna
sequenc
modul
type
immun
respons
helper
th
cell
abil
plasmid
dna
hold
multipl
gene
exampl
hemagglutinin
multipl
influenza
strain
offer
easi
way
mixandmatch
antigen
new
combin
secondli
plasmid
dna
vaccin
design
noninfecti
encod
antigen
interest
oppos
live
attenu
vaccin
viral
carrier
system
requir
sever
antigen
encod
simultan
thirdli
addit
provid
code
sequenc
antigen
interest
plasmid
dna
serv
physic
vector
also
possibl
function
adjuv
improv
immun
respons
inde
dna
vaccin
increasingli
test
primeboost
strategi
aim
amelior
immun
respons
mani
type
vaccin
may
possibl
manipul
dna
increas
adjuv
effect
addit
multipl
immunostimulatori
sequenc
final
dna
vaccin
excel
safeti
profil
display
toxic
immunogen
drawback
often
associ
viral
unlik
type
vaccin
includ
recombin
subunit
vaccin
use
viral
vector
dna
vaccin
contain
heterolog
protein
compon
host
may
respond
thu
like
live
vaccin
immun
induc
mhc
class
ii
respons
without
risk
inher
live
viru
streamlin
manufactur
perhap
advantag
gain
term
product
time
make
dna
vaccin
particular
relev
combat
emerg
infecti
agent
new
virul
influenza
strain
current
develop
time
turn
raw
ingredi
finish
vaccin
surgeri
fridg
readi
administr
patient
almost
month
fig
includ
month
product
month
qualiti
control
month
product
finish
month
control
agenc
test
potenti
month
distribut
shown
dna
vaccin
could
reduc
initi
product
period
one
reduc
total
process
time
eight
month
plasmid
dna
technolog
appli
influenza
vaccin
mani
live
could
save
first
eight
month
global
pandem
total
total
product
cost
vaccin
manufactur
incur
downstream
advanc
purif
process
dna
target
affin
chromatographi
enabl
highli
select
facil
purif
dna
vaccin
even
complex
feed
enabl
captur
purif
vastli
differ
type
dna
one
chromatograph
step
without
copurif
contamin
genom
dna
rna
protein
endotoxin
process
could
potenti
elimin
need
purif
polish
stage
requir
tradit
vaccin
catch
remain
howev
area
concern
use
dna
vaccin
includ
poor
translat
mous
model
wherea
case
dna
vaccin
elicit
strong
immun
respons
mice
respons
disappoint
primat
human
becom
clear
howev
immun
respons
amelior
via
inclus
plasmid
gene
encod
variou
immunostimulatori
molecul
addit
concern
possibl
dna
vaccin
could
elicit
product
antibodi
encod
antigen
instead
doublestrand
plasmid
dna
molecul
could
compromis
repeat
use
dna
vaccin
booster
also
serious
prompt
develop
autoimmun
diseas
also
appear
dna
molecul
contain
certain
base
eg
unmethyl
dinucleotid
specif
base
sequenc
context
cpg
motif
abil
activ
tolllik
also
preferenti
activ
thelper
cell
type
immun
respons
learn
underli
mechan
possibl
cours
dna
vaccin
may
design
exploit
effect
adjuv
activ
promot
certain
type
immun
protect
anoth
gener
problem
low
effici
cell
transform
plasmid
dna
affect
manner
administr
dosag
formul
plasmid
dna
physic
eg
inject
gene
gun
electropor
aerosol
deliveri
chemic
eg
cation
lipid
polym
condens
agent
biolog
eg
use
cellular
transport
mechan
approach
explor
overcom
low
target
cell
specif
futur
current
influenza
vaccin
product
method
base
old
technolog
product
issu
associ
outmod
technolog
eg
requir
inactiv
attenu
vaccin
delay
deliveri
batch
appropri
qualiti
hen
egg
compromis
util
respond
public
health
crisi
flu
pandem
contrast
plasmid
dna
revers
engin
use
recombin
techniqu
manufactur
purifi
quickli
allow
vaccin
product
much
shorter
time
inde
product
time
could
reduc
nine
month
convent
vaccin
littl
one
month
dna
vaccin
notwithstand
product
advantag
plasmid
dna
vaccin
also
offer
greater
flexibl
sever
differ
antigen
prepar
use
standard
recombin
techniqu
greater
control
immun
process
excel
safeti
profil
anim
earli
phase
human
studi
stabil
resist
extrem
temperatur
thu
facilit
storag
transport
distribut
remot
area
current
sever
dna
vaccin
develop
veterinari
purpos
around
dozen
dna
vaccin
human
develop
worldwid
none
yet
proceed
beyond
phase
trial
gene
therapi
show
total
number
trial
use
plasmid
dna
increas
also
percentag
trial
gene
therapi
trial
fig
indic
interest
plasmid
dna
vector
gain
momentum
rel
vector
eg
retroviru
adenoviru
dna
vaccin
realiz
potenti
sever
challeng
lie
ahead
firstli
perhap
import
product
must
pass
latestag
trial
regulatori
scrutini
approv
market
human
popul
secondli
plasmid
contract
manufactur
need
ramp
product
alreadi
experienc
rapid
growth
introduc
patent
highresolut
purif
procedur
speed
process
manufactur
econom
standpoint
cost
per
dose
dna
vaccin
must
brought
level
econom
competit
convent
vaccin
wider
use
nucleic
acid
pharmaceut
applic
gene
therapi
gene
correct
like
lead
process
advanc
technolog
transfer
reduc
cost
advanc
may
includ
develop
process
creat
much
shorter
fragment
dna
elicit
respons
much
larger
plasmid
dna
molecul
lead
high
transform
effici
improv
dosag
time
yield
dose
creat
per
hour
process
equip
issu
address
like
barrier
entri
vaccin
develop
market
could
lower
also
countri
would
abl
produc
vaccin
rather
reli
small
number
produc
happen
becom
pain
clear
research
center
public
health
institut
govern
vaccin
manufactur
throughout
world
particularli
countri
strength
vaccin
product
need
collabor
take
action
toward
solv
current
vaccin
product
problem
confront
loom
pandem
countri
area
name
manufactur
capac
influenza
vaccin
australia
europ
japan
north
america
group
tradit
strength
vaccin
product
lead
way
develop
forwardlook
innov
address
woefulli
inadequ
product
capac
shortterm
longterm
global
health
world
time
break
tradit
mold
dna
vaccin
need
proactiv
explor
knowledg
transfer
share
clinic
applic
acceler
altern
reli
vaccin
manufactur
capac
hopelessli
outdat
inadequ
face
influenza
pandem
